Do Not Switch from Propranolol to Gabapentin for Anxiety
I strongly recommend against discontinuing propranolol and switching to gabapentin for anxiety treatment in this patient. The evidence clearly shows that propranolol lacks robust efficacy for anxiety disorders beyond performance anxiety, and gabapentin is only a second-line option with limited evidence. More importantly, the patient is already on escitalopram 15 mg—a first-line, evidence-based treatment that should be optimized before considering any other changes.
Why This Switch Is Not Recommended
Propranolol's Limited Role in Anxiety
The most recent systematic review and meta-analysis 1 found no evidence for beneficial effects of beta-blockers compared to placebo or benzodiazepines in patients with social phobia or panic disorder. An earlier meta-analysis 2 similarly concluded that "the quality of evidence for the efficacy of propranolol at present is insufficient to support the routine use of propranolol in the treatment of any of the anxiety disorders."
The Canadian Clinical Practice Guideline explicitly deprecates propranolol for anxiety disorders based on negative evidence 3. Beta-blockers like propranolol and atenolol are only beneficial for performance anxiety specifically, not generalized anxiety disorders 4.
Gabapentin's Weak Evidence Base
Gabapentin is listed as a second-line agent in the Canadian CPG 3, meaning it should only be considered after first-line treatments (SSRIs/SNRIs) have failed or are not tolerated. The evidence supporting gabapentin for anxiety is substantially weaker than for SSRIs.
The Real Problem: Suboptimal First-Line Treatment
Your patient is on escitalopram 15 mg—a first-line SSRI with strong evidence for anxiety disorders 3, 5. However, this may not be an adequate dose. Before abandoning evidence-based treatment:
- Optimize the escitalopram dose: Many patients require higher doses for full response
- Ensure adequate trial duration: SSRIs typically require 8-12 weeks for full effect
- Assess adherence and tolerability
Specific Risks of This Switch
Propranolol Withdrawal Concerns
The FDA label warns that abrupt discontinuation of propranolol can cause exacerbation of angina and even myocardial infarction 6. Even without known cardiovascular disease, "it may be prudent to follow the above advice in patients considered at risk of having occult atherosclerotic heart disease." Propranolol must be tapered gradually over at least a few weeks, not stopped abruptly.
Drug Interaction Risk
There is a documented case report of dystonia occurring when propranolol and gabapentin were combined 7, suggesting potential synergistic effects between these medications. While you're planning to switch rather than combine, this highlights unpredictable interactions.
Additionally, gabapentin has been shown to enhance the cardiovascular effects of beta-blockers, causing greater reductions in blood pressure, heart rate, and cardiac contractility 8. This is relevant during any transition period.
Ropinirole Considerations
Your patient is on ropinirole 0.5 mg, which commonly causes somnolence (40% incidence), dizziness, confusion, and hallucinations 9. Gabapentin also causes significant sedation. Adding gabapentin while the patient is on ropinirole could compound CNS depressant effects, increasing fall risk and cognitive impairment.
What You Should Do Instead
Optimize the escitalopram first:
- Consider increasing to 20 mg daily if tolerated
- Ensure the patient has had an adequate 8-12 week trial at therapeutic dose
- Add cognitive behavioral therapy (CBT), which has strong evidence for anxiety disorders 3, 5
If escitalopram fails after optimization:
- Switch to another first-line SSRI (sertraline, paroxetine) or SNRI (venlafaxine) 3
- Consider pregabalin (stronger evidence than gabapentin) as a second-line option
- Benzodiazepines (clonazepam, alprazolam) are second-line options for refractory cases 3
If you must discontinue propranolol:
- Taper gradually over 2-4 weeks minimum 6
- Monitor for rebound tachycardia, hypertension, or anxiety worsening
- Do not assume propranolol was providing meaningful anxiety benefit—it likely wasn't
Common Pitfall: Clinicians often cycle through multiple medications without optimizing first-line treatments. The evidence strongly supports maximizing SSRI therapy and adding CBT before moving to agents with weaker evidence like gabapentin.